ArticleMolecular neurobiology2025
Deciphering Ferroptosis-Related Astrocyte Subpopulations and Diagnostic Biomarkers in Parkinson's Disease through RNA Transcriptomics.
Article in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Comorbid mechanisms of neuroinflammation and astrocytic ferroptosis in neurological disorders: A vicious cycle (Review).Biomedical reports · 2026Review
- Dual-Pathway Astrocyte Failure in Parkinson's Disease: Therapeutic Targeting of Nrf2/TFEB Suppression and cGAS-STING/Ferroptosis Activation.Molecular neurobiology · 2026Review
- Synergistic Effects of Plant Polysaccharides and Probiotics: A Novel Dietary Approach for Parkinson's Disease Intervention.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Microglia, Astrocytes, and Oligodendrocytes in Parkinson's Disease: Neuroinflammatory Crosstalk and Emerging Therapeutic Strategies.Biomolecules · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Parkinson`s disease (PD) is the second most prevalent neurodegenerative disorder, and increasing evidence indicates that glial activation plays a significant role in ferroptosis and the subsequent neurodegeneration. In this study, we aimed to identify ferroptosis-related astrocytes exhibiting elevated inflammation scores in PD patients. The single-cell and bulk RNA transcriptomic profiles of PD samples were collected from the Gene Expression Omnibus database. We characterized seven cell types in the substantia nigra region of PD and normal samples, and discovering that astrocytes from the PD group interacted with microglia and oligodendrocytes. Furthermore, we identified five distinct astrocyte subpopulations: Astro-C0, -C1, -C2, -C3, and -C4. The Astro-C1 subpopulation was found to be correlated with ferroptosis. Trajectory analysis revealed that the Astro-C4 subpopulation clustered at the anterior end of the differentiation trajectory, followed by a gradual transition to the Astro-C0 and Astro-C1 subpopulations. Additionally, we identified ferroptosis-related genes (NEAT1, HSPB1, HSPA5, and ATF4) within the Astro-C1 subpopulation and noting that NEAT1, HSPB1, and HSPA5 exhibited diagnostic potential for PD. Our findings indicated that lipopolysaccharide (LPS) treatment exacerbated astrocyte ferroptosis, as evidenced by elevated levels of Fe2 + , MDA, lipid ROS, and intracellular ROS, along with decreased MMP in PD. Moreover, the high expression of NEAT1 and low levels of HSPB1, ATF4, and HSPA5, might serve as a diagnostic indicator of ferroptosis in PD. Our study revealed that inflammation might exacerbate astrocyte ferroptosis. Additionally, NEAT1, HSPB1, and HSPA5 might serve as diagnostic markers for ferroptosis in PD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.